EID3 and autoimmune disease: Thus, these findings strongly suggest that Eid3, which is highly expressed in MSCs, impacts cellular differentiation by regulating transcription factors and that Eid3 derived from MSC-sEVs could be used as a therapeutic agent to treat Th17 cell-associated autoimmune diseases.